Indolic uremic solutes increase tissue factor production in endothelial cells by the aryl hydrocarbon receptor pathway

Kidney International

Volumn 84, Issue 4, 2013, Pages 733-744

  Gondouin, Bertrand ^a,b   Cerini, Claire ^a   Dou, Laetitia ^a   Sallée, Marion ^a,b   Duval Sabatier, Ariane ^a,b   Pletinck, Anneleen ^c   Calaf, Raymond ^a   Lacroix, Romaric ^a   Jourde Chiche, Noémie ^b   Poitevin, Stéphane ^a   Arnaud, Laurent ^a   Vanholder, Raymond ^c   Brunet, Philippe ^a,b   Dignat George, Françoise ^a   Burtey, Stéphane ^a,b  

^a AIX MARSEILLE UNIVERSITY   (France)

^b HÔPITAL DE LA CONCEPTION   (France)

^c GHENT UNIVERSITY HOSPITAL   (Belgium)

Author keywords

aryl hydrocarbon receptor; tissue factor; uremic solutes

Indexed keywords

AROMATIC HYDROCARBON; INDICAN; INDOLEACETIC ACID; MESSENGER RNA; THROMBOPLASTIN;

ADULT; AGED; AHR GENE; AHRR GENE; ARTICLE; CARDIOVASCULAR RISK; CELL NUCLEUS; CHRONIC KIDNEY DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; CRR7 GENE; CYP1A1 GENE; CYP1A2 GENE; CYP1B1 GENE; CYTOPLASM; ENDOTHELIUM CELL; FEMALE; GENE; GENE ACTIVITY; GENE EXPRESSION; GENE FUNCTION; GENE IDENTIFICATION; GENE TARGETING; GENE TRANSLOCATION; HUMAN; HUMAN CELL; MALE; MEMBRANE MICROPARTICLE; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PTGS2 GENE; TF GENE; TGFB3 GENE; TIPARP GENE; TRANSCRIPTION REGULATION; UPREGULATION;

ADULT; AGED; AGED, 80 AND OVER; BENZOQUINONES; CASE-CONTROL STUDIES; CELLS, CULTURED; DIOXINS; ENDOTHELIUM, VASCULAR; FEMALE; HUMANS; INDICAN; INDOLEACETIC ACIDS; LACTAMS, MACROCYCLIC; LEUKOCYTES, MONONUCLEAR; MALE; MIDDLE AGED; POLYMERASE CHAIN REACTION; RECEPTORS, ARYL HYDROCARBON; RENAL INSUFFICIENCY, CHRONIC; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; THROMBOPLASTIN; TISSUE ARRAY ANALYSIS; UMBILICAL VEINS; UP-REGULATION;

EID: 84885314579     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2013.133     Document Type: Article

References (51)

1. Massy Z, Argiles A, Spasovski G et al. Chronic kidney disease as cause of cardiovascular morbidity and mortality. Nephrol Dial Transplant 2005; 20: 1048-1056.
2. van der Velde M, Astor BC, Woodward M et al. Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis. Lancet 2010; 375: 2073-2081.
3. Sciarrettaa S, Valenti V, Tocci G et al. Association of renal damage with cardiovascular diseases independent of individual cardiovascular risk profile in hypertension: data from the Italy-Developing Education and awareness on MicroAlbuminuria in patients with hypertensive Disease study. J Hypertens 2010; 28: 251-258.
4. Stam F, van Guldener C, Schalkwijk CG et al. Impaired renal function is associated with markers of endothelial dysfunction and increased inflammatory activity. Nephrol Dial Transplant 2003; 18: 892-898.
5. Dou L, Bertrand E, Cerini C et al. The uremic solutes p-cresol and indoxylsulfate inhibit endothelial proliferation and wound repair. Kidney Int 2004; 65: 442-451.
6. Panichi V, Rizza GM, Paoletti S et al. Chronic inflammation and mortality in haemodialysis: effect of different renal replacement therapies. Results from the RISCAVID study. Nephrol Dial Transplant 2008; 23: 2337-2343.
7. Baskin E, Duman O, Besbas N et al. Hypercoagulopathy in a hemodialysis patient: are elevations in factors VII and VIII effective? Nephron 1999; 83: 180.
8. Segarra A, Chacon P, Martinez-Eyarre C et al. Circulating levels of plasminogen activator inhibitor type-1, tissue plasminogen activator, and thrombomodulin in hemodialysis patients: biochemical correlations and role as independent predictors of coronary artery stenosis. J Am Soc Nephrol 2001; 12: 1255-1263.
9. Malyszko J, Malyszko JS, Hryszko T et al. Thrombin activatable fibrinolysis inhibitor (TAFI) and markers of endothelial cell injury in dialyzed patients with diabetic nephropathy. Thromb Haemostasis 2004; 91: 480-486.
10. Mercier E, Branger B, Vecina F et al. Tissue factor coagulation pathway and blood cells activation state in renal insufficiency. Hematol J 2001; 2: 18-25.
11. Wattanakit K, Cushman M, Stehman-Breen C et al. Chronic kidney disease increases risk for venous thromboembolism. J Am Soc Nephrol 2008; 19: 135-140.
12. Vanholder R, De Smet R, Glorieux G et al. Review on uremic toxins: classification, concentration, and interindividual variability. Kidney Int 2003; 63: 1934-1943.
13. Dou L, Jourde-Chiche N, faure V et al. The uremic solute indoxyl sulfate induces oxidative stress in endothelial cells. J Throm Haemost 2007; 5: 1302-1308.
14. Faure V, Dou L, Sabatier F et al. Elevation of circulating endothelial microparticles in patients with chronic renal failure. J Throm Haemost 2006; 4: 566-573.
15. Barreto FC, Barreto DV, Liabeuf S et al. Serum indoxyl sulfate is associated with vascular disease and mortality in chronic kidney disease patients. Clin J Am Soc Nephrol 2009; 4: 1551-1558.
16. Jourde-Chiche N, Dou L, Sabatier F et al. Levels of circulating endothelial progenitor cells are related to uremic toxins and vascular injury in hemodialysis patients. J Throm Haemost 2009; 7: 1576-1584.
17. Chu AJ. Tissue factor upregulation drives a thrombosis-inflammation circuit in relation to cardiovascular complications. Cell Biochem Funct 2006; 24: 173-192.
18. Masai N, Tatebe J, Yoshino G et al. Indoxyl sulfate stimulates monocyte chemoattractant protein-1 expression in human umbilical vein endothelial cells by inducing oxidative stress through activation of the NADPH oxidase-nuclear factor-kB pathway. Circ J 2010; 74: 2216-2224.
19. Tumur Z, Shimizu H, Enomoto A et al. Indoxyl sulfate upregulates expression of ICAM-1 and MCP-1 by oxidative stress-induced NF-kappaB activation. Am J Nephrol 2010; 31: 435-441.
20. Bogdanov VY, Balasubramanian V, Hathcock J et al. Alternatively spliced human tissue factor: a circulating, soluble, thrombogenic protein. Nat Med 2003; 9: 458-462.
21. Pongratz I, Mason GG, Poellinger L. Dual roles of the 90-kDa heat shock protein hsp90 in modulating functional activities of the dioxin receptor. Evidence that the dioxin receptor functionally belongs to a subclass of nuclear receptors which require hsp90 both for ligand binding activity and repression of intrinsic DNA binding activity. Chemistry Biol Chem 1992; 267: 13728-13734.
22. Hughes D, Guttenplan JB, Marcus CB et al. Heat shock protein 90 inhibitors suppress aryl hydrocarbon receptor-mediated activation of CYP1A1 and CYP1B1 transcription and DNA adduct formation. Cancer Prev Res 2008; 1: 485-493.
23. Bock KW, Kö hle C. The mammalian aryl hydrocarbon (Ah) receptor: from mediator of dioxin toxicity toward physiological functions in skin and liver. Biol Chem 2009; 390: 1225-1235.
24. Mechtcheriakova D, Schabbauer G, Lucerna M et al. Specificity, diversity, and convergence in VEGF and TNF-alpha signaling events leading to tissue factor up-regulation via EGR-1 in endothelial cells. FASEB J 2001; 15: 230-24.
25. Ollivier V, Wang J, Manly D et al. Detection of endogenous tissue factor levels in plasma using the calibrated automated thrombogram assay. Thromb Res 2010; 125: 90-96.
26. Schroeder JC, Dinatale BC, Murray IA et al. The uremic toxin 3-indoxyl sulfate is a potent endogenous agonist for the human aryl hydrocarbon receptor. Biochemistry 2010; 49: 393-400.
27. Vega-Ostertag M, Casper K, Swerlick R et al. Involvement of p38 MAPK in the up-regulation of tissue factor on endothelial cells by antiphospholipid antibodies. Arthritis Rheum 2005; 52: 1545-1554.
28. Eto M, Kozai T, Cosentino F et al. Statin prevents tissue factor expression in human endothelial cells: role of Rho/Rho-kinase and Akt pathways. Circulation 2002; 105: 1756-1759.
29. Vogel CF, Sciullo E, Matsumura F. Involvement of RelB in aryl hydrocarbon receptor-mediated induction of chemokines. Biochem Biophys Res Commun 2007; 363: 722-726.
30. Wu D, Li W, Lok P et al. AhR deficiency impairs expression of LPS-induced inflammatory genes in mice. Biochem Biophys Res Commun 2011; 410: 358-363.
31. Patel RD, Murray IA, Flaveny CA et al. Ah receptor represses acute-phase response gene expression without binding to its cognate response element. Lab Invest 2009; 89: 695-707.
32. Huang G, Elferink CJ. A novel nonconsensus xenobiotic response element capable of mediating aryl hydrocarbon receptor-dependent gene expression. Mol Pharmacol 2012; 81: 338-347.
33. Pawlak K, Mysliwiec M, Pawlak D. Hypercoagulability is independently associated with kynurenine pathway activation in dialysed uraemic patients. Thromb Haemostasis 2009; 102: 49-55.
34. Opitz CA, Litzenburger UM, Sahm F et al. An endogenous tumourpromoting ligand of the human aryl hydrocarbon receptor. Nature 2011; 478: 197-203.
35. Wu D, Nishimura N, Kuo V et al. Activation of aryl hydrocarbon receptor induces vascular inflammation and promotes atherosclerosis in apolipoprotein e-/-mice. Arterioscler Thromb Vasc Biol 2011; 31: 1260-1267.
36. Pelclova D, Fenclova Z, Preiss J et al. Lipid metabolism and neuropsychological follow-up study of workers exposed to 2,3,7,8- tetrachlordibenzo-p-dioxin. Int Arch Occup Environ Health 2002; 75: S60-66.
37. Boitano AE, Wang J, Romeo R et al. Aryl hydrocarbon receptor antagonists promote the expansion of human hematopoietic stem cells. Science 2010; 329: 1345-1348.
38. Zwicker JI, Trenor CC 3rd, Furie BC et al. Tissue factor-bearing microparticles and thrombus formation. Arterioscler Thromb Vasc Biol 2011; 31: 728-733.
39. Solovey A, Gui L, Key NS et al. Tissue factor expression by endothelial cells in sickle cell anemia. J Clin Invest 1998; 101: 1899-1904.
40. Shet AS, Aras O, Gupta K et al. Sickle blood contains tissue factor-positive microparticles derived from endothelial cells and monocytes. Blood 2003; 102: 2678-2683.
41. Solovey A, Kollander R, Shet A et al. Endothelial cell expression of tissue factor in sickle mice is augmented by hypoxia/reoxygenation and inhibited by lovastatin. Blood 2004; 104: 840-846.
42. Chantrathammachart P, Mackman N, Sparkenbaugh E et al. Tissue factor promotes activation of coagulation and inflammation in a mouse model of sickle cell disease. Blood 2012; 120: 636-646.
43. Steffel J, Luscher TF, Tanner FC. Tissue factor in cardiovascular diseases: molecular mechanisms and clinical implications. Circulation 2006; 113: 722-731.
44. Drake TA, Hannani K, Fei HH et al. Minimally oxidized low-density lipoprotein induces tissue factor expression in cultured human endothelial cells. Am J Pathol 2011; 138: 601-607.
45. Wilcox JN, Smith KM, Schwartz SM et al. Localization of tissue factor in the normal vessel wall and in the atherosclerotic plaque. Proc Natl Acad Sci USA 1989; 86: 2839-2843.
46. Thiruvikraman S, Guha VA, Roboz J et al. In situ localization of tissue factor in human atherosclerotic plaques by binding of digoxigeninlabeled factors VIIa and X. Lab invest 1996; 75: 451-461.
47. Hutter R, Valdiviezo C, Sauter BV et al. Caspase-3 and tissue factor expression in lipid-rich plaque macrophages: evidence for apoptosis as link between inflammation and atherothrombosis. Circulation 2004; 109: 2001-2008.
48. Jeanpierre E, Le Tourneau T, Zawadzki C et al. Dietary lipid lowering modifies plaque phenotype in rabbit atheroma after angioplasty: a potential role of tissue factor. Circulation 2003; 108: 1740-1745.
49. Jiang DJ, Cao Y, Xin HY et al. Symmetric dimethylarginine induces tissue factor expression in monocytes via NF-kappaB-dependent pathway: Role in acute coronary syndromes. Atherosclerosis 2009; 205: 554-560.
50. Bierhaus A, Humpert PM, Arnold B et al. Advanced glycation end product receptor-mediated cellular dysfunction. Ann NY Acad Sci 2005; 1043: 676-680.
51. Jaffe EA, Nachman RL, Becker CG et al. Culture of human endothelial cells derived from umbilical veins. Identification by morphologic and immunologic criteria. J Clin Invest 1973; 52: 2745-2756.